PF-04191834 + naproxen

**PF-04191834 + naproxen** is a combination of two small molecule drugs: PF-04191834, an investigational inhibitor of Arachidonate 5-lipoxygenase (5-LOX), and naproxen, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. PF-04191834 acts by inhibiting the 5-LOX enzyme, which blocks the synthesis of leukotrienes, inflammatory mediators implicated in conditions such as osteoarthritis. Naproxen works mainly through reversible inhibition of cyclooxygenase-1 and -2 (COX-1 and COX-2), decreasing prostaglandin precursor formation to provide anti-inflammatory and pain-relieving effects. This combination was clinically studied for the treatment of osteoarthritis of the knee, aiming to enhance anti-inflammatory efficacy and symptom control by targeting complementary inflammatory pathways[7][5].